# A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N

Source: https://onco.cc/trials/nct06829459/  
OnCo record `nct06829459` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Glumetinib run by Shanghai JMT-Bio Inc. in non-small-cell lung cancer and small-cell lung cancer, now recruiting.

## Summary

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs is a phase 3 interventional study registered as NCT06829459 by Shanghai JMT-Bio Inc., with 350 participants planned, started 2025-04-03. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06829459
- Phase: 3
- Setting: A Randomized, Controlled, Open-label Phase III Clinical Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients With MET Amplification and/or Overexpression After Resistance to EGFR-TKIs
- Sponsor: Shanghai JMT-Bio Inc.
- Enrolled: 350

## Sources

- ClinicalTrials.gov NCT06829459: https://clinicaltrials.gov/study/NCT06829459

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Glumetinib](https://onco.cc/drugs/glumetinib/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct06829459.json